Evidence map›Paper›PMID 36394597›Full record

ReviewRheumatology international2023

Curcuma as an anti-inflammatory component in treating osteoarthritis.

Zrinka Djukić Koroljević, Katarina Jordan, Jakov Ivković, Darija Vranešić Bender, Porin Perić

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07183215 (Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07183215 phase2 / phase3enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu

TypeinterventionalSponsorGadjah Mada UniversityRan2025 to 2025Enrolled72ConditionsOsteoarthritisArmsCurcuminoid Standardized Turmeric Capsules, Placebo
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Zrinka Djukić KoroljevićSpecijalna Bolnica Sveta Katarina, Branimirova 71E, 10000, Zagreb, Hrvatska, Croatia. zrinka.djukickoroljevic@svkatarina.hr.ORCID 0000-0001-7737-2599
Katarina JordanOpća Bolnica Zadar, Bože Peričića 5, 23000, Zadar, Croatia.
Jakov IvkovićSpecijalna Bolnica za Medicinsku Rehabilitaciju Naftalan, Omladinska 23a, 10310, Ivanić-Grad, Hrvatska, Croatia.
Darija Vranešić BenderKlinički Bolnički Centar Zagreb, Kišpatićeva 12, 10000, Zagreb, Hrvatska, Croatia.
Porin PerićKlinički Bolnički Centar Zagreb, Kišpatićeva 12, 10000, Zagreb, Hrvatska, Croatia.
University Hospital Centre Zagreb · HROpća bolnica Karlovac · HROpća Bolnica Zadar · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is nowadays the most common musculoskeletal progressive condition. In recent decades, incidence and prevalence of OA have increased significantly. It is estimated that the prevalence of OA among adults older than 60 is 12%, affecting about 240 million people globally. The cause has not been fully elucidated, and therefore, there is no cure at the moment. It is a multifactorial degenerative disease with an inflammatory component mediated by numerous proinflammatory and anti-inflammatory cytokines, chemokines, and growth factors. OA is not yet fully understood; therefore, therapeutic interventions are aimed primarily at reducing symptoms and slowing the progression of joint destruction. Of the therapeutic options available, the most often prescribed are nonsteroidal antirheumatic drugs, which have numerous side effects. Therefore, a need for a safe, effective substance is differentiated, which will be used in adjuvant treatment, but also in disease prevention, and which will comparatively have no or fewer side effects. One such substance is curcumin, a hydrophobic polyphenol that forms the active component of the rhizome of the Curcuma longa plant. Several studies have shown its potent antioxidant and anti-inflammatory effect, non-toxicity, and safety at high daily doses. In addition to blocking chondrocyte apoptosis, curcumin also blocks the expression of cyclooxygenase, prostaglandin E-2 and proinflammatory cytokines in chondrocytes, potentially alleviating symptomatic diseases. Although there are significant variations in quality, methodology, and research results conducted on curcumin efficiency in OA treatment, curcumin is primarily recommended as systematic short-term and medium-term adjuvant therapy that reduces inflammatory biochemical factors. Reducing inflammation leads to better pain regulation and improved joint function, significantly reducing standard prescribed doses of drugs. The most researched daily doses of curcumin intake are 1000-2000 mg/day, which would also be the doses that most of the authors recommend. Further research is needed to determine the preventive role of curcumin in the pathogenesis of OA, the effects of long-term usage of curcumin in preventive purposes and treatment of osteoarthritis, as well as to determine optimal therapeutic dosages.

Indexed as

CurcuminMusculoskeletal DiseasesOsteoarthritisAdultAnti-Inflammatory AgentsCurcumaCytokinesHumansAnti-Inflammatory AgentsCurcuminCytokinesCurcumaCurcuminFood as medicineMedicinal substanceOsteoarthritis

Identifiers

PMID36394597
OpenAlexW4309246049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.